Rapid Micro Biosystems, Inc. revenue
Rapid Micro Biosystems, Inc.'s revenue was $33.6m in fiscal 2025, up 19.7% on the year before. Since fiscal 2020 ($16.1m) it has grown at a compound 15.9% a year. Over the last twelve months it was $35.2m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $23.4M | 69.7% | ▲ 25.1% |
| Services | $10.2M | 30.3% | ▲ 9.0% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $13.4M | 40.0% | ▲ 26.3% |
| Switzerland | $6M | 17.9% | ▲ 6.2% |
| All Other Countries | $5.8M | 17.2% | ▼ 13.1% |
| Germany | $5.8M | 17.2% | ▲ 89.2% |
| Japan | $2.6M | 7.7% | ▲ 26.4% |
From Rapid Micro Biosystems, Inc.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Rapid Micro Biosystems, Inc. | $35.2m | 16.1% | 22.5% |
| Maxcyte, Inc. | $31.1m | -13.2% | -8.6% |
| Omniab, Inc. | $40.2m | 90.6% | -14.7% |
| Bionano Genomics, Inc. | $30.2m | 10.0% | -1.4% |
| Alpha Teknova, Inc. | $43.7m | 12.3% | 3.7% |
| Champions Oncology, Inc. | $60.7m | 6.7% | 4.8% |
Compare with peers
- Maxcyte, Inc. revenue
- Omniab, Inc. revenue
- Bionano Genomics, Inc. revenue
- Alpha Teknova, Inc. revenue
- Champions Oncology, Inc. revenue
Head to head: MXCT vs RPIDOABI vs RPIDBNGO vs RPIDRPID vs TKNO
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies